Consensus evidence-based guidelines for insulin therapy in patients with type 1 diabetes mellitus as per Indian clinical practice

Journal of Association of Physicians of India

Volumn 62, Issue , 2014, Pages 26-33

  Kanungo, Alok ^a   Jhingan, Ashok ^b   Sahay, Rakesh Kumar ^c   Muruganathan, A ^d   Das, Ashok Kumar ^e  

^a Kanungo Institute of Diabetes Specialities Hospital   (India)

^b Diabetes Research Centre   (India)

^c OSMANIA MEDICAL COLLEGE   (India)

^d AG Hospital   (India)

^e JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

CONSENSUS DEVELOPMENT; DIABETES MELLITUS, TYPE 1; EVIDENCE BASED MEDICINE; HUMAN; HYPOGLYCEMIA; INDIA; PRACTICE GUIDELINE;

DIABETES MELLITUS, TYPE 1; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INDIA; INSULIN; PRACTICE GUIDELINES AS TOPIC;

EID: 84925232478     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Aschner P, Horton E, Leiter LA, Munro N, Skyler JS; Global Partnership for Effective Diabetes Management. Practical steps to improving the management of type 1 diabetes: recommendations from the Global Partnership for Effective Diabetes Management. Int J ClinPract 2010; 64: 305-315.
2. IDF, 2012. http://www. idf. org/diabetesatlas/diabetes-young-global-perspective. Last accessed February 18, 2014.
3. Krishna P, Roopakala, Prasanna Kumar KM. Dyslipidemia in type 1 diabetes mellitus in the young. Int J DiabDev Countries 2005; 25: 110-112.
4. Kalra S, Kalra B, Sharma A. Prevalence of type 1 diabetes mellitus in Karnal district, Haryana state, India. Diabetol Metab Syndr 2010; 2: 14.
5. Rao PV, Ushabala P, Ahuja MMS. A decade of epidemiology of diabetes. Intl J Diab Dev Countries 1991; 10: 41-47.
6. Sridhar GR, Nagamani G. Clinical association of autoimmune diseases with diabetes mellitus analysis from southern India. Ann NY Acad Sci 2002; 958: 390-392.
7. Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag 2009; 12: 103-110.
8. Kapur A. Economic analysis of diabetes care. Indian J Med Res 2007; 125: 473-482.
9. Ramachandran A, Mary S, Yamuna A, Mary S, Ping Z. Cost-effectiveness of the interventions in the primary prevention of diabetes among Asian Indians. Diabetes Care 2007; 30: 2548-2552.
10. DCCT Research Group. The effects of intensive diabetes treatment on the development and progression of long-term complication in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. N Engl J Med 1993; 329: 977-986.
11. HandelsmanY, Mechanick JI, Blonde L, et al. AACE Task Force for Developing Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011; 17: 1-53.
12. American Diabetes Association. Standards of medical care in diabetes-2013. Diabetes Care 2013; 36: S11-66.
13. Cheng AY, Lau DC. The canadian diabetes association 2013 clinical practice guidelinesraising the bar and setting higher standards! Can J Diabetes 2013; 37: 137-138.
14. Global IDF/ISPAD Guideline for Diabetes in Childhood and Adolescence, 2012. http://www. idf. org/sites/default/files/Diabetes-in-Childhood-and-Adolescence-Guidelines. pdf. Last accessed on February 18, 2014.
15. IS PAE. Type 1 diabetes mellitus in children and adolescents in India, 2011. http://www. ispae. org. in/old/Diabetes%20guidelines%20for%20Web. pdf. Last accessed on February 18, 2014.
16. Clinical practice guidelines: Type 1 diabetes in children and adolescents, 2005. http://www. nhmrc. gov. au/_files_nhmrc/publications/attachments/cp102. pdf. Last accessed on February 18, 2014.
17. NI CE. Type 1 diabetes: diagnosis and management of type 1 diabetes in children, young people and adults, 2012. http://www. nice. org. uk/nicemedia/live/10944/29390/29390. pdf. Last accessed on February 18, 2014.
18. Silverstein J, Klingensmith G, Copeland K, et al. American Diabetes Association. Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. Diabetes Care 2005; 28: 186-212.
19. Scibilia J, Finegold D, Dorman J, Becker D, Drash A. Why do children with diabetes die? Acta Endocrinol Suppl (Copenh) 1986; 279: 326-333.
20. Institute of Health Economics. Insulin pump therapy for type 1 diabetes. Edmonton AB: Institute of Health Economics. 2012. http://www. ihe. ca/documents/Insulin%20Pump%20 Therapy%20March%202012. pdf. Last accessed on February 18, 2014.
21. Vehik K, Cuthbertson D, Boulware D, et al. TEDDY, TRIGR, Diabetes Prevention Trial-Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups. Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth. Diabetes Care 2012; 35: 1821-1825.
22. Harjutsalo V, Reunanen A, Tuomilehto J. Differential transmission of type 1 diabetes from diabetic fathers and mothers to their offspring. Diabetes 2006; 55: 1517-1524.
23. Decochez K, Truyen I, van der Auwera B, et al. Belgian Diabetes Registry. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005; 48: 687-694.
24. Bingley PJ. Interactions of age, islet cell antibodies, insulin autoantibodies, and first-phase insulin response in predicting risk of progression to IDDM in ICA+ relatives: the ICARUS data set. Islet Cell Antibody Register Users Study. Diabetes 1996; 45: 1720-1728.
25. Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial-Type 1. Diabetes Care 2005; 28: 1068-1076.
26. Murphy HR, Rayman G, Skinner TC. Psycho-educational interventions for children and young people with type 1 diabetes. Diabet Med 2006; 23: 935-943.
27. Hampson SE, Skinner TC, Hart J, et al. Effects of educational and psychosocial interventions for adolescents with diabetes mellitus: a systematic review. Health Technol Assess 2001; 5: 1-79.
28. Winkley K, Ismail K, Landau S; Eisler I. Psychological interventions to improve glycaemic control in patients with type 1 diabetes: systematic review and meta-analysis of randomised controlled trials. BMJ 2006; 333: 65.
29. Laffel LM, Vangsness L, Connell A, Goebel-Fabbri A, Butler D, Anderson BJ. Impact of ambulatory, family-focused teamwork intervention on glycemic control in youth with type 1 diabetes. J Pediatr 2003; 142: 409-416.
30. Shobhana R, Rama RP, Vijay V, Snehalatha C, Ramachandran A. Diabetes education session for young IDDM probands and their family members in a developing country: an evaluation. Practical Diabetes Int 1997; 14: 123-125.
31. Jordan LV, Robertson M, Grant L, et al. The Tayside insulin management course: an effective education programme in type 1 diabetes. Int J Clin Pract 2013; 67: 462-468.
32. Hermanns N, Kulzer B; Ehrmann D, Bergis-Jurgan N, Haak T. The effect of a diabetes education programme (PRIMAS) for people with type 1 diabetes: Results of a randomized trial. Diabetes Res Clin Pract 2013; 102: 149-157.
33. Nakatani Y, Matsumura M, Monden T, Aso Y, Nakamoto T. Improvement of Glycemic Control by Re-education in Insulin Injection Technique in Patients with Diabetes Mellitus. Adv Ther 2013; 30: 897-906.
34. Boden S, Lloyd CE, Gosden C, Macdougall C, Brown N, Matyka K. The concerns of school staffin caring for children with diabetes in primary school. Pediatr Diabetes 2012; 13: e6-13.
35. Aycan Z, Önder A, Çetinkaya S, et al. Assessment of the knowledge of diabetes mellitus among school teachers within the scope of the managing diabetes at school program. J Clin Res Pediatr Endocrinol 2012; 4: 199-203.
36. Mastrandrea L, Yu J, Behrens T, et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. Diabetes Care 2009; 32: 1244-1249.
37. Levitsky LL, Misra M, Wolfsdorf JI, Hoppin AG. Management of type 1 diabetes mellitus in children and adolescents. In: Up To Date, Basow DS (Ed), Waltham, MA, 2011.
38. Gallen I. The evolution of insulin treatment in type 1 diabetes: the advent of analogues. The Br J Diabetes Vasc Dis 2004; 4: 378-381.
39. Heller S, Koenen C, Bode B. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. Clin Ther 2009; 31: 2086-2097.
40. Wolffenbuttel BH, van Ouwerkerk BM, Veldhuyzen BF, Geelhoed-Duijvestijn PH, Jakobsen G, van Doorn LG. Comparative effects of two different multiple injection regimens on blood glucose control and patient acceptance in type 1 diabetes. Diabet Med 1990; 7: 695-699.
41. Wolfsdorf JI, Laffel LM, Pasquarello C, Vernon A, Herskowitz RD. Split-mixed insulin regimen with human ultralente before supper and NPH (isophane) before breakfast in children and adolescents with IDDM. Diabetes Care 1991; 14: 1100-1106.
42. Razavi Z, Ahmadi M. Efficacy of Thrice-daily versus Twice-daily Insulin Regimens on Glycohemoglobin (Hb A1c) in Type 1 Diabetes Mellitus: A Randomized Controlled Trial. Oman Med J 2011; 26: 10-13.
43. Kinsley BT, McKenna TJ. Premixed insulin preparations and glycaemic control in type 1 diabetes mellitus. Ir Med J 1999; 92: 369-371.
44. Bhatia E, Aggarwal A. Insulin Therapy for Patients with Type 1 Diabetes. JAPI 2007; 55: 29-34, 39-40.
45. Herbst K, Hirsch IB. Insulin Strategies for Primary Care Providers. Clinical Diabetes 2002; 20: 11-17.
46. Yadav S, Parakh A. Insulin therapy. Indian Pediatrics 2006; 43: 863-872.
47. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004; 21: 769-775.
48. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomised open crossover trial in type 1 diabetic subjects on basal-bolus therapy. Diabetes Care 2001; 24: 296-301.
49. Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and RHI) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
50. Kalra S. Advances in insulin therapy. Recent Adv Endocrinol 2013; 63: 925-927.
51. Weight gain associated with intensive therapy in the diabetes control and complications trial. The DCCT Research Group. Diabetes Care 1988; 11: 567-573.
52. Home P, Bartley P, Russell-Jones D, et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomised clinical trial. Diabetes Care 2004; 27: 1081-1087.
53. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
54. Pieber TR, Draeger E, Kristensen A, Grill V. Comparison of three multiple injection regimens for type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 2005; 22: 850-857.
55. Dornhorst A, Lüddeke HJ, Honka M, et al. PREDICTIVE Study Group. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study. Curr Med Res Opin 2008; 24: 369-376.
56. Bode BW, Buse JB, Fisher M, et al. BEGIN® Basal-Bolus Type 1 Trial Investigators. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(®) Basal-Bolus Type 1): 2-year results of a randomised clinical trial. Diabet Med 2013; 30: 1293-1297.
57. Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab 2013; 15: 175-184.
58. Birkeland KI, Home PD, Wendisch U, et al. Insulin degludec in type 1 diabetes: a randomised controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 2011; 34: 661-665.
59. Heller S, Buse J, Fisher M, et al. BEGIN Basal-Bolus Type 1 Trial Investigators. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012; 379: 1489-1497.
60. De Leeuw I, Vague P, Selam JL, et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7: 73-82.
61. Mathieu C, Hollander P, Miranda-Palma B, et al; NN1250-3770 (BEGIN: Flex T1) Trial Investigators. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomised, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab 2013; 98: 1154-1162.
62. Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab 2012; 14: 859-864.
63. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006; 66: 31-49.
64. Boehm B, Home P, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002; 19: 393-399.
65. Indian National Consensus Group. Premix Insulin: Initiation and Continuation Guidelines for Management of Diabetes in Primary Care. JAPI 2009; 57: 42-46.
66. Chen JW, Lauritzen T, Bojesen A, Christiansen JS. Multiple mealtime administration of biphasic insulin aspart 30 versus traditional basal-bolus human insulin treatment in patients with type 1 diabetes. Diabetes Obes Metab 2006; 8: 682-689.
67. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16.
68. Hermansen K, Vaaler S, Madsbad S, et al. Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes. Metabolism 2002; 51: 896-900.
69. Morgan CL; Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ. Clinical effectiveness of biphasic insulin aspart 30: 70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study. Clin Ther 2011; 33: 27-35.
70. Nord E, Hanson U, Persson B. A simplified model for management of women with gestational diabetes at the primary care level. Diabetes Res 1991; 17: 175-179.
71. UK Hypoglycemia Study Group. Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration. Diabetologia 2007; 50: 1140-1147.
72. Akram K, Pedersen-Bjergaard U, Carstensen B, Borch-Johnsen K, Thorsteinsson B. Frequency and risk factors of severe hypoglycaemia in insulin-treated type 2 diabetes: A cross-sectional survey. Diabes Med 2006; 23: 750-756.
73. Adverse events and their association with treatment regimens in the diabetes control and complications trial. Diabetes Care 1995; 18: 1415-1427.
74. The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286.
75. Hermanns N, Kulzer B, Kubiak T, Krichbaum M, Haak T. The effect of an education programme (HyPOS) to treat hypoglycaemia problems in patients with type 1 diabetes. Diabetes Metab Res Rev 2007; 23: 528-538.
76. Hermanns N, Kulzer B, Krichbaum M, Kubiak T, Haak T. Long-term effect of an education program (HyPOS) on the incidence of severe hypoglycemia in patients with type 1 diabetes. Diabetes Care 2010; 33: e36.
77. Floyd B, Chandra P, Hall S, et al. Comparative analysis of the efficacy of continuous glucose monitoring and self-monitoring of blood glucose in type 1 diabetes mellitus. J Diabetes Sci Technol 2012; 6: 1094-1102.
78. Liu D, McManus RM, Ryan EA. Improved counter-regulatory hormonal and symptomatic responses to hypoglycaemia in patients with insulin-dependent diabetes mellitus after 3 months of less strict glycemic control. Clin Invest Med 1996; 19: 71-82.
79. Lingenfelser T, Buettner U, Martin J, et al. Improvement of impaired counter-regulatory hormone response and symptom perception by short-term avoidance of hypoglycaemia in IDDM. Diabetes Care 1995; 18: 321-325.
80. Schachinger H, Hegar K, Hermanns N, et al. Randomized controlled clinical trial of Blood Glucose Awareness Training (BGAT III) in Switzerland and Germany. J Behav Med 2005; 28: 587-594.
81. Toth GH. Continuous subcutaneous insulin infusion in children and adolescents with type 1 diabetes: Do the benefits outweigh the risks? Paediatr Child Health 2005; 10: 28-30.
82. Kapitza C, Fein S, Heinemann L, Schleusener D, Levesque S, Strange P. Basal-prandial insulin delivery in type 2 diabetes mellitus via the V-Go: a novel continuous subcutaneous infusion device. J Diabetes Sci Technol 2008; 2: 40-46.
83. Meneghini L, Sparrow-Bodenmiller J. Practical aspects and considerations when switching between continuous subcutaneous insulin infusion and multiple daily injections. Diabetes Technol Ther 2010; 12: S109-114.
84. SI GN. Management of diabetes: A national clinical guideline, 2010. http://www. sign. ac. uk/pdf/sign116. pdf. Last accessed on February 18, 2014.
85. Monami M, Lamanna C, Marchionni N, Mannucci E. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in type 1 diabetes: a meta-analysis. Acta Diabetol 2010; 47: 77-81.
86. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials. BMJ 2002; 324: 705.
87. Hirsch IB, Bode BW, Garg S, et al; Insulin Aspart CSII/MDI Comparison Study Group. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injections of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII. Diabetes Care 2005; 28: 533-538.
88. Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomised controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care 2005; 28: 1277-1281.
89. Wilson DM, Buckingham BA, Kunselman EL, et al. A two-center randomised controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care 2005; 28: 15-19.
90. Todres L, Keen S, Kerr D. Continuous subcutaneous insulin infusion in Type 1diabetes: patient experiences of 'living with a machine'. Diabet Med 2010; 27: 1201-1204.
91. Opipari-Arrigan L, Fredericks EM, Burkhart N, Dale L, Hodge M, Foster C. Continuous subcutaneous insulin infusion benefits quality of life in preschool-age children with type 1. diabetes mellitus. Pediatr Diabetes 2007; 8: 377-383.
92. Kesavadev J, Das AK, Unnikrishnan R, et al. Use of insulin pumps in India: suggested guidelines based on experience and cultural differences. Diabetes Technol Ther 2010; 12: 823-831.
93. Pickup JC, Sutton AJ. Severe hypoglycaemia and glycaemic control in type 1 diabetes: meta-analysis of multiple daily insulin injections compared with continuous subcutaneous insulin infusion. Diabet Med 2008; 25: 765-774.
94. Doyle EA, Weinzimer SA, Steffen AT Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558.
95. Hanaire-Broutin H, Melki V, Bessières-Lacombe S, Tauber JP. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes. Diabetes Care 2000; 23: 1232-1235.
96. Minkina-Pedras M, Jarosz-Chobot P, Małecka-Tendera E, Deja G. [Assessment of metabolic control and safety of continuous subcutaneous insulin infusion in prepubertal children with type 1 diabetes mellitus]. Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw. 2005; 11: 171-176.
97. Klonoff DC, Buckingham B, Christiansen JS, et al. Endocrine Society. Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 2968-2979.
98. Rewers M, Pihoker C, Donaghue K, Hana's R, Swift P, Klingensmith GJ. Assessment and monitoring of glycemic control in children and adolescents with diabetes. Pediatr Diabetes 2009; 10: 71-81.
99. Pickup JC, Freeman SC, Sutton AJ. Glycaemic control in type 1 diabetes during real time continuous glucose monitoring compared with self-monitoring of blood glucose: metaanalysis of randomised controlled trials using individual patient data. BMJ 2011; 343: d3805.
100. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476.